Jazz Pharmaceuticals’ Price Targets Rise to $224–$275 on Q4 Beats, Ziihera Outlook
Analysts initiated an Overweight rating with a $224 price target, then raised Jazz Pharmaceuticals’ targets to $226, $255 and $275 after fiscal Q4’s modest top- and bottom-line beats and FY26 mid-point guidance about 3% below consensus. Stable CNS sales and Ziihera-driven oncology growth with tumor-type readouts due in 2027.
1. Overweight Initiation and $224 Target
Analysts initiated coverage with an Overweight rating and a $224 price target, highlighting Jazz’s stable central nervous system product sales as a reliable revenue stream.
2. Price Target Increases to $226, $255, $275
Subsequent target raises to $226, $255 and $275 reflect growing optimism on Jazz Pharmaceuticals’ valuation following fiscal Q4’s modest top- and bottom-line beats.
3. Fiscal Q4 Results and FY26 Guidance
Jazz reported slight Q4 revenue and earnings beats, and issued FY26 mid-point revenue guidance roughly 3% below consensus, which analysts still deem solid for funding ongoing operations and pipeline development.
4. Ziihera Oncology Growth Prospects
Ziihera’s oncology program is expected to deliver significant tumor-type readouts in 2027, underpinning long-term growth forecasts beyond the core CNS franchise.